Abstract
Diabetic cardiac myopathy (DCM) is a potent and independent risk factor in developing cardiovascular disease and heart failure. Despite successful management of comorbid cardiovascular risks, patients with diabetes still see increased incidents of heart failure. Hyperglycemia damages endothelial cells, causing inflammation and transcriptional derangement which drive endothelial cells to take on a mesenchymal phenotype, the process of EndMT. Cells with a mesenchymal phenotype then become a source of cardiac fibroblast-like cells that contribute to cardiac fibrosis, a defining characteristic of DCM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
